Close Menu

Breaking News

University of Oxford researchers said they are weeks away from completing clinical validation of a coronavirus molecular test based on RT-LAMP technology.

Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.

The Cas9 variant can target nearly all PAM sites in the genome, allowing the researchers to edit previously inaccessible disease-relevant genetic variants.

Alterations that arise that have high fitness are also associated with an increased risk of developing acute myeloid leukemia.

Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.

The kit, which is CE marked, is designed to detect the virus' ORF1ab, N, and E genes, and can process 96 samples within two hours.

The agency provided an overview of its policies regarding COVID-19 test regulations, as well as additional color and clarification, in a webinar.

The test, which uses an Applied Bioystems TaqPath assay and real-time PCR technology, detects nucleic acid from SARS-CoV-2, the virus that causes COVID-19.

Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.

The team believes that the project will find genetic factors involved in the development of severe COVID-19 in patients that lack risk factors. 

The funds will go toward general corporate purposes, possibly including repayment of a portion of its outstanding commercial paper borrowings.

Now, the assay can also be used with the Applied Biosystems 7500 Standard from Thermo Fisher Scientific, Roche's LightCycler 480, and Qiagen's Rotor-Gene Q.

For FY 2019, the firm's revenues dropped 11 percent to $19.2 million from $21.5 million in 2018, matching analysts' expectations. 

Q4 Revenue growth was driven by 46 percent growth in commercial test volume and 34 percent growth in average insurance reimbursement per patient.

The company reported a net loss of $8.0 million, or $.15 per share, as it saw increased costs associated with its transition to commercial test provision.

The company said Q4 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

The researchers, from various institutions in China, said they hope their data will contribute to the completion of the international Human Cell Atlas project.

An integrated analysis involving prostate cancer patients from China highlighted frequent FOXA1 mutations and deletions in two other genes.

The company, known for clinical chemistry and molecular biology diagnostic kits, is currently working on two test kits for SARS-CoV-2.

The drug, tepotinib, will now be available to treat advanced non-small cell lung cancer patients in Japan with MET exon 15 skipping alterations.

Yourgene will use its manufacturing facility at Citylabs in Manchester to ramp up production of the test, which was developed by Novacyt's Primerdesign division.

The companies will work together to develop a next-generation sequencing-based companion diagnostic for an undisclosed cancer therapy.

OpGen also reported full-year growth was driven by revenue increases for its Acuitas AMR Gene Panel and Acuitas Lighthouse informatics platform.

The assay, which is also CE-IVD-marked, detects SARS-CoV-2 ORF1a and N genes and has a limit of detection of 20 copies per mL using a 400 µL sample.

The firm licensed the assay for detecting SARS-CoV-2 from Hackensack Meridian Health and will adapt it for the T2Dx instrument.

Pages

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.